3/18
08:00 am
dtil
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
Low
Report
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
3/17
06:17 pm
dtil
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript [Seeking Alpha]
3/13
05:05 pm
dtil
Precision BioSciences (DTIL) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
High
Report
Precision BioSciences (DTIL) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/12
03:47 pm
dtil
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates [Yahoo! Finance]
Low
Report
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates [Yahoo! Finance]
3/12
07:23 am
dtil
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/12
07:00 am
dtil
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Medium
Report
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
3/11
07:13 am
dtil
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program [Yahoo! Finance]
Medium
Report
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program [Yahoo! Finance]
3/11
07:01 am
dtil
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Medium
Report
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
3/10
07:28 am
dtil
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 [Yahoo! Finance]
High
Report
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 [Yahoo! Finance]
3/10
07:01 am
dtil
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
High
Report
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
3/9
04:39 pm
dtil
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 [Yahoo! Finance]
High
Report
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 [Yahoo! Finance]
3/9
04:15 pm
dtil
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
High
Report
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
3/9
07:16 am
dtil
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event [Yahoo! Finance]
Medium
Report
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event [Yahoo! Finance]
3/9
07:01 am
dtil
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
Medium
Report
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
3/2
07:16 am
dtil
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis [Yahoo! Finance]
Medium
Report
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis [Yahoo! Finance]
3/2
07:01 am
dtil
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
Medium
Report
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
2/18
07:01 am
dtil
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Medium
Report
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
2/11
07:01 am
dtil
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Low
Report
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
2/2
09:36 am
dtil
Registration for SOHO 2026 is now open; Register by June 10, 2026 to receive early registration rates [Yahoo! Finance]
Medium
Report
Registration for SOHO 2026 is now open; Register by June 10, 2026 to receive early registration rates [Yahoo! Finance]
1/12
08:55 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
1/12
07:01 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Medium
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
1/7
08:00 am
dtil
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Low
Report
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
12/29
03:42 am
dtil
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
Low
Report
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]